Press Releases Items Per Page 102550 News Category FinancialGeneral Year None20192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results Mar 01, 2018 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2017 on Thursday, March 1, 2018, After Close of U.S.-Based Financial Markets Feb 21, 2018 Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214 Feb 14, 2018 Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Jan 03, 2018 Nektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare Conference in New York City Nov 27, 2017 Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Company's Immuno-Oncology Pipeline Nov 22, 2017 First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 Nov 11, 2017 Nektar to Webcast Presentation at Jefferies 2017 London Healthcare Conference Nov 10, 2017 Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017 Nov 07, 2017 New Data Featuring Nektar Therapeutics' Wholly-Owned Immuno-Oncology Pipeline to be Presented at the 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting Nov 07, 2017 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »